GUFICBIO2024-01-012024-03-31 GUFICBIO2024-01-012024-03-31 GUFICBIO2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member GUFICBIO2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member GUFICBIO2024-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 509079 GUFICBIO NOTLISTED Gufic Biosciences Limited Equity 2023-04-01 2024-03-31 2024-05-29 2024-05-22 INR Lakhs Yearly 19:15:00 20:40:00 2024-05-29 2024-05-29 true Cash Flow Indirect Declaration of unmodified opinion Single segment The Company's business activity falls within a single operating segment i.e. Pharmaceuticals 2024-01-01 2024-03-31 Audited Consolidated 1949935000.00 8814000.00 1958749000.00 909494000.00 143411000.00 -166754000.00 296033000.00 36474000.00 43421000.00 425479000.00 1687558000.00 271191000.00 0.00 271191000.00 73000000.00 -2269000.00 70731000.00 0.00 200460000.00 0.00 0.00 0.00 0.00 200460000.00 -4039000.00 196421000.00 0.00 0.00 100278000.00 1 2.00 2.00 0.00 0.00 2.00 2.00 1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder. 2. The above results for the quarter and year ended March 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 29, 2024. The Statutory Auditors have carried out audit of the results for quarter and year ended March 31, 2024. 3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals. 4. The Board of Directors at its meeting held on May 29, 2024 has recommended a final dividend of Re. 0.10/- per equity share i.e., @ 10% on the face value of Rs. 1/- each, for the financial year 2023-24, subject to the approval of the shareholders at the ensuing Annual General Meeting. 5. The Company has incorporated Gufic UK Limited ( GUL ) in United Kingdom on March 15, 2022, Gufic Ireland Limited ( GIL ) in Ireland on March 02, 2023, Veira Life FZE ( VLF ) in Dubai, UAE on March 25, 2024 and Gufic Prime Private Limited (“GPPL”) in India on November 18, 2023, with the intention of making GUL, GIL and VLF its Wholly Owned Subsidiaries and GPPL as its Subsidiary Company. As of March 31, 2024, neither investment have been made in GIL, VLF and GPPL nor they have begun their business operations. Consequently, there was no need to consolidate the accounts of GIL, VLF and GPPL with the Company. Whereas, on September 13, 2023, the Company invested in GUL by subscribing to its shares. Consequently, the consolidated financial results for the quarter and financial year ended March 31, 2024, have been prepared by the Company considering the financials of GUL. 6. Pursuant to the approval received from the Board of Directors, shareholders and the Stock Exchanges on which the shares of the Company are listed and in accordance with the applicable provisions of Companies Act, 2013 and Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Board of Directors, on October 11, 2023, allotted 33,33,000 fully paid-up equity shares of the Company having face value of Rs. 1/- each at the price of Rs. 300/- (Rupees Three Hundred Only) per equity share including premium of Rs. 299/- (Rupees Two Hundred Ninety-Nine Only) per equity share, to M/s. Motilal Oswal Financial Services Limited, Non Promoter of the Company on preferential basis. The Company has fully utilised the entire proceeds of the Preferential Issue for specified object without any deviation. 7. The equity shares and basic/diluted earnings per share has been presented in accordance with Ind AS - 33-Earning per share. 8. The figures for the quarter ended March 31, 2024 and March 31, 2023 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to -date figures up to the third quarter ended December 31, 2023 and December 31, 2022 respectively, which were subjected to limited review. 9. Previous year/quarters figures have been regrouped/reclassified, wherever necessary. Single segment 2023-04-01 2024-03-31 Audited Consolidated 8066657000.00 21772000.00 8088429000.00 3413226000.00 580609000.00 -94883000.00 1096263000.00 153599000.00 170172000.00 1612728000.00 6931714000.00 1156715000.00 0.00 1156715000.00 263704000.00 31655000.00 295359000.00 0.00 861356000.00 0.00 0.00 0.00 0.00 861356000.00 -4039000.00 857317000.00 0.00 0.00 100278000.00 1 5225328000.00 8.74 8.74 0.00 0.00 8.74 8.74 Other Expenses 425479000.00 Other Expenses 1612728000.00 1532742000.00 3070567000.00 0.00 0.00 56192000.00 0.00 0.00 0.00 17843000.00 0.00 4144000.00 88675000.00 110662000.00 0.00 150459000.00 4920622000.00 2004821000.00 0.00 3299353000.00 11368000.00 123472000.00 3734000.00 0.00 3437927000.00 0.00 562046000.00 6004794000.00 0.00 0.00 10925416000.00 100278000.00 5225328000.00 5325606000.00 5325606000.00 1539631000.00 0.00 165287000.00 1704918000.00 153770000.00 20633000.00 1879321000.00 1630714000.00 1662687000.00 180675000.00 3474076000.00 173597000.00 47363000.00 25453000.00 3720489000.00 0.00 0.00 5599810000.00 10925416000.00 153599000.00 -170246000.00 -1532419000.00 0.00 0.00 0.00 0.00 0.00 0.00 400332000.00 0.00 0.00 0.00 170172000.00 0.00 0.00 0.00 0.00 5854000.00 0.00 4000.00 13992000.00 0.00 0.00 0.00 0.00 2834000.00 22995000.00 0.00 -960875000.00 195840000.00 0.00 0.00 0.00 270436000.00 0.00 -74596000.00 0.00 0.00 0.00 10000000.00 0.00 0.00 0.00 0.00 45662000.00 1126946000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 29000.00 10014000.00 0.00 57351000.00 0.00 -1023890000.00 0.00 0.00 999900000.00 0.00 0.00 0.00 0.00 0.00 423436000.00 368366000.00 20624000.00 69045000.00 9694000.00 126172000.00 0.00 -5600000.00 823835000.00 -274651000.00 0.00 -274651000.00 286019000.00 11368000.00 -5397000.00 -5397000.00 -1358000.00 -1358000.00 0.00 0.00